Ausgabe 2/2014
Inhalt (17 Artikel)
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
João Vinagre, Vasco Pinto, Ricardo Celestino, Marta Reis, Helena Pópulo, Paula Boaventura, Miguel Melo, Telmo Catarino, Jorge Lima, José Manuel Lopes, Valdemar Máximo, Manuel Sobrinho-Simões, Paula Soares
Necrotizing sialometaplasia-like change of the esophageal submucosal glands is associated with Barrett’s esophagus
David R. Braxton, Dana C. Nickleach, Yuan Liu, Alton B. Farris III
Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma
Hiroshi Yoshida, Noriko Yamamoto, Hirokazu Taniguchi, Ichiro Oda, Hitoshi Katai, Ryoji Kushima, Hitoshi Tsuda
Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC
Konrad Steinestel, Jochen K. Lennerz, Stefan Eder, Klaus Kraft, Annette Arndt
Non-sarcomatous spindle cell morphology in conventional lung adenocarcinoma: a clinicopathological study
Susumu Matsukuma, Kiyohaya Obara, Kimi Kato, Yoshiro Ohshika, Hiroaki Takeo, Satoshi Tsuchiya, Kimiya Sato
Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors
V. Pulkkinen, S. Ezer, L. Sundman, J. Hagström, S. Remes, C. Söderhäll, G. Dario, C. Haglund, J. Kere, J. Arola
Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype
Miguel Rito, Fernando Schmitt, António E. Pinto, Saudade André
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma
Gian Franco Zannoni, Giuseppina Improta, Gaia Chiarello, Angela Pettinato, Marco Petrillo, Paolo Scollo, Giovanni Scambia, Filippo Fraggetta
Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder
Antonio Lopez Beltran, Liang Cheng, Rodolfo Montironi, Ana Blanca, Manuel Leva, Morgan Rouprêt, Jorge Fonseca, Alfredo Vidal, Carmen L. Menendez, Judit Pallares, Enrico Bollito, Carlos Reymundo, Rafael J Luque, Eva Comperat
FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer
Yann Neuzillet, Bas W. G. van Rhijn, Nadia L. Prigoda, Bharati Bapat, Liyang Liu, Peter J. Bostrom, Neil E. Fleshner, Brenda L. Gallie, Alexandre R. Zlotta, Michael A. S. Jewett, Theo H. van der Kwast
Foamy cell (hibernoma-like) change is a rare histopathological feature in renal cell carcinoma
Fredrik Petersson, Maris Sperga, Stela Bulimbasic, Petr Martinek, Marian Svajdler, Naoto Kuroda, Milan Hora, Roderick Simpson, Tomáš Tichy, Kvetoslava Peckova, Jindrich Branzovsky, Kristyna Pivovarcikova, Pavla Rotterova, Bohuslava Kokoskova, Kevin Bauleth, Dusan Martincok, Vincent Nagy, Michal Michal, Ondrej Hes
Limited role for histopathological examination of re-excision specimens of completely excised melanomas
A. C. de Waal, R. Vossen, K. K. H. Aben, L. A. L. M. Kiemeney, M. M. van Rossum, W. A. M. Blokx
Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion
Navid Sadri, Julieta Barroeta, Svetlana D. Pack, Zied Abdullaev, Bishwanath Chatterjee, Raghunath Puthiyaveettil, John S. Brooks, Frederic G. Barr, Paul J. Zhang
Diffuse glutamine synthetase overexpression restricted to areas of peliosis in a β-catenin-activated hepatocellular adenoma: a potential pitfall in glutamine synthetase interpretation
Ryan S. Berry, Rama R. Gullapalli, Jin Wu, Katherine Morris, Joshua A. Hanson
Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC?
Esther Diana Rossi, Tommaso Bizzarro, Guido Fadda, Luigi Maria Larocca, Fernando Schmitt
Erratum to: “Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors
V. Pulkkinen, S. Ezer, L. Sundman, J. Hagström, S. Remes, C. Söderhäll, D. Greco, C. Haglund, J. Kere, J. Arola